AnalyticsCompugen To Present Clinical Data from anti-TIGIT COM902 Monotherapy and Triple Combination Dose Escalation Studies at SITC 2021

HOLON, IsraelOct. 1, 2021 /PRNewswire/ — Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that new clinical and preclinical data will be presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, which will be held on November 10-14, 2021.

Poster Presentation Details:

Title: COM902 (anti-TIGIT antibody) monotherapy – preliminary evaluation of safety, tolerability, pharmacokinetics, and receptor occupancy in patients with advanced solid tumors (NCT04354246).
Abstract Number: 477
Lead Author: Dumbrava, E, E 
Date: Friday, November 12, 2021

Title: COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability, and pharmacokinetics in patients with advanced solid tumors (NCT04570839). 
Abstract Number: 478
Lead Author: Dumbrava, E, E
Date: Saturday, November 13, 2021

Title: Novel DNAM-1 axis member, PVRIG, is potentially a dominant checkpoint involved in stem-like memory T cells – dendritic cell interaction.
Abstract Number: 252 
Lead Author: Alteber, Z
Date: Saturday, November 13, 2021


Leave a Reply

Your email address will not be published. Required fields are marked *